Hyaline membrane disease and pneumonia in the setting of pneumothorax
AI-generated summary
A 2-day-old term infant (2670g, small-for-gestational-age) presented with respiratory distress at 11 hours of life. A capillary blood gas at 1:14pm showed mixed respiratory and metabolic acidosis indicating decompensation, but this was not recognized or escalated in the medical notes. The infant deteriorated with cyanosis, requiring intubation, ventilation, and NICU admission. Bilateral pneumothoraces and persistent pulmonary hypertension were identified and managed. Surfactant was administered at 2:05pm on day 2, but at a suboptimal dose (90-100mg/kg vs guideline 150mg/kg for his weight) and without repeat dosing. The underlying diagnosis of hyaline membrane disease (HMD) was not adequately considered despite atypical presentation. The coroner found that earlier recognition of abnormal blood gas results, earlier consideration of HMD as a differential diagnosis, and administration of adequate surfactant doses with repeat dosing may have prevented deterioration and death.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.
Delay in recognition and escalation of abnormal blood gas results at 1:14pm on 10 August 2020 showing respiratory decompensation
Failure to consider hyaline membrane disease as underlying diagnosis despite clinical features
Inadequate appreciation of chest X-ray findings suggestive of RDS (reticulogranular ground glass opacities and alveolar atelectasis)
Insufficient surfactant dosing relative to hospital guidelines and manufacturer recommendations
Absence of repeat surfactant dosing despite ongoing respiratory deterioration
Surfactant dosing influenced by cost considerations and vial waste rather than optimal clinical dosing
Diagnostic fixation on bilateral pneumothoraces and PPHN limiting consideration of underlying lung pathology
Coroner's recommendations
That the Royal Women's Hospital, PIPER and Safer Care Victoria review their guidelines relating to surfactant to ensure prompt administration to newborns who require intubation for respiratory distress and that initial and repeat doses accord with the latest available evidence bearing in mind interstate and European guidelines and the manufacturer's user guide.
That parents of newborns be informed of the importance of and encouraged to notify carers in relation to any changes in colour or breathing, supported by visual signs to aid education.
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.